Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 74 entries
Sorted by: Best Match Show Resources per page
[No title available]

Frontiers in physiology

Quarto N, Shailendra S, Meyer NP, Menon S, Renda A, Longaker MT.
PMID: 30374308
Front Physiol. 2018 Oct 15;9:1426. doi: 10.3389/fphys.2018.01426. eCollection 2018.

Craniofacial development is a program exquisitely orchestrated by tissue contributions and regulation of genes expression. The basic helix-loop-helix (bHLH) transcription factor Twist1 expressed in the skeletal mesenchyme is a key regulator of craniofacial development playing an important role during...

Cite
Quarto N, Shailendra S, Meyer NP, et al. . Front Physiol. 2018;9:1426doi: 10.3389/fphys.2018.01426.
Quarto, N., Shailendra, S., Meyer, N. P., Menon, S., Renda, A., & Longaker, M. T. (2018). . Frontiers in physiology, 91426. https://doi.org/10.3389/fphys.2018.01426
Quarto, Natalina, et al. "." Frontiers in physiology vol. 9 (2018): 1426. doi: https://doi.org/10.3389/fphys.2018.01426
Quarto N, Shailendra S, Meyer NP, Menon S, Renda A, Longaker MT. . Front Physiol. 2018 Oct 15;9:1426. doi: 10.3389/fphys.2018.01426. eCollection 2018. PMID: 30374308; PMCID: PMC6196243.
Copy Download .nbib Format: NLM
CGM Initiation Soon After Type 1 Diabetes Diagnosis Results in Sustained CGM Use and Wear Time.

Diabetes care

Prahalad P, Addala A, Scheinker D, Hood KK, Maahs DM.
PMID: 31558548
Diabetes Care. 2020 Jan;43(1):e3-e4. doi: 10.2337/dc19-1205. Epub 2019 Sep 26.

No abstract available.

Cite
Prahalad P, Addala A, Scheinker D, et al. CGM Initiation Soon After Type 1 Diabetes Diagnosis Results in Sustained CGM Use and Wear Time. Diabetes Care. 2019;43(1):e3-e4doi: 10.2337/dc19-1205.
Prahalad, P., Addala, A., Scheinker, D., Hood, K. K., & Maahs, D. M. (2020). CGM Initiation Soon After Type 1 Diabetes Diagnosis Results in Sustained CGM Use and Wear Time. Diabetes care, 43(1), e3-e4. https://doi.org/10.2337/dc19-1205
Prahalad, Priya, et al. "CGM Initiation Soon After Type 1 Diabetes Diagnosis Results in Sustained CGM Use and Wear Time." Diabetes care vol. 43,1 (2020): e3-e4. doi: https://doi.org/10.2337/dc19-1205
Prahalad P, Addala A, Scheinker D, Hood KK, Maahs DM. CGM Initiation Soon After Type 1 Diabetes Diagnosis Results in Sustained CGM Use and Wear Time. Diabetes Care. 2020 Jan;43(1):e3-e4. doi: 10.2337/dc19-1205. Epub 2019 Sep 26. PMID: 31558548; PMCID: PMC7011198.
Copy Download .nbib Format: NLM
Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study.

Journal of clinical medicine

Sung KC, Lee MY, Lee JY, Lee SH, Kim SH, Kim SH.
PMID: 30987010
J Clin Med. 2019 Apr 02;8(4). doi: 10.3390/jcm8040445.

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of elevated alanine aminotransferase (ALT), but the clinical utility of ALT in detecting and following individuals with NAFLD remains unclear. We conducted a retrospective analysis of 30,988 men and...

Cite
Sung KC, Lee MY, Lee JY, et al. Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study. J Clin Med. 2019;8(4)doi: 10.3390/jcm8040445.
Sung, K. C., Lee, M. Y., Lee, J. Y., Lee, S. H., Kim, S. H., & Kim, S. H. (2019). Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study. Journal of clinical medicine, 8(4), . https://doi.org/10.3390/jcm8040445
Sung, Ki-Chul, et al. "Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study." Journal of clinical medicine vol. 8,4 (2019). doi: https://doi.org/10.3390/jcm8040445
Sung KC, Lee MY, Lee JY, Lee SH, Kim SH, Kim SH. Utility of ALT Concentration in Men and Women with Nonalcoholic Fatty Liver Disease: Cohort Study. J Clin Med. 2019 Apr 02;8(4). doi: 10.3390/jcm8040445. PMID: 30987010; PMCID: PMC6517922.
Copy Download .nbib Format: NLM
Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System.

Diabetes technology & therapeutics

Schoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cherñavvsky DR, Beck RW, DeBoer MD.
PMID: 33689454
Diabetes Technol Ther. 2021 Jul;23(7):475-481. doi: 10.1089/dia.2020.0646. Epub 2021 Mar 09.

No abstract available.

Cite
Schoelwer MJ, Kanapka LG, Wadwa RP, et al. Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technol Ther. 2021;23(7):475-481doi: 10.1089/dia.2020.0646.
Schoelwer, M. J., Kanapka, L. G., Wadwa, R. P., Breton, M. D., Ruedy, K. J., Ekhlaspour, L., Forlenza, G. P., Cobry, E. C., Messer, L. H., Cengiz, E., Jost, E., Carria, L., Emory, E., Hsu, L. J., Weinzimer, S. A., Buckingham, B. A., Lal, R. A., Oliveri, M. C., Kollman, C. C., Dokken, B. B., Cherñavvsky, D. R., Beck, R. W., DeBoer, M. D. (2021). Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes technology & therapeutics, 23(7), 475-481. https://doi.org/10.1089/dia.2020.0646
Schoelwer, Melissa J, et al. "Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System." Diabetes technology & therapeutics vol. 23,7 (2021): 475-481. doi: https://doi.org/10.1089/dia.2020.0646
Schoelwer MJ, Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cobry EC, Messer LH, Cengiz E, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, Buckingham BA, Lal RA, Oliveri MC, Kollman CC, Dokken BB, Cherñavvsky DR, Beck RW, DeBoer MD. Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technol Ther. 2021 Jul;23(7):475-481. doi: 10.1089/dia.2020.0646. Epub 2021 Mar 09. PMID: 33689454; PMCID: PMC8252894.
Copy Download .nbib Format: NLM
Relationship Between Coronary Atheroma, Epicardial Adipose Tissue Inflammation, and Adipocyte Differentiation Across the Human Myocardial Bridge.

Journal of the American Heart Association

McLaughlin T, Schnittger I, Nagy A, Zanley E, Xu Y, Song Y, Nieman K, Tremmel JA, Dey D, Boyd J, Sacks H.
PMID: 34726081
J Am Heart Assoc. 2021 Nov 16;10(22):e021003. doi: 10.1161/JAHA.121.021003. Epub 2021 Nov 02.

Background Inflammation in epicardial adipose tissue (EAT) may contribute to coronary atherosclerosis. Myocardial bridge is a congenital anomaly in which the left anterior descending coronary artery takes a "tunneled" course under a bridge of myocardium: while atherosclerosis develops in...

Cite
McLaughlin T, Schnittger I, Nagy A, et al. Relationship Between Coronary Atheroma, Epicardial Adipose Tissue Inflammation, and Adipocyte Differentiation Across the Human Myocardial Bridge. J Am Heart Assoc. 2021;10(22):e021003doi: 10.1161/JAHA.121.021003.
McLaughlin, T., Schnittger, I., Nagy, A., Zanley, E., Xu, Y., Song, Y., Nieman, K., Tremmel, J. A., Dey, D., Boyd, J., & Sacks, H. (2021). Relationship Between Coronary Atheroma, Epicardial Adipose Tissue Inflammation, and Adipocyte Differentiation Across the Human Myocardial Bridge. Journal of the American Heart Association, 10(22), e021003. https://doi.org/10.1161/JAHA.121.021003
McLaughlin, Tracey, et al. "Relationship Between Coronary Atheroma, Epicardial Adipose Tissue Inflammation, and Adipocyte Differentiation Across the Human Myocardial Bridge." Journal of the American Heart Association vol. 10,22 (2021): e021003. doi: https://doi.org/10.1161/JAHA.121.021003
McLaughlin T, Schnittger I, Nagy A, Zanley E, Xu Y, Song Y, Nieman K, Tremmel JA, Dey D, Boyd J, Sacks H. Relationship Between Coronary Atheroma, Epicardial Adipose Tissue Inflammation, and Adipocyte Differentiation Across the Human Myocardial Bridge. J Am Heart Assoc. 2021 Nov 16;10(22):e021003. doi: 10.1161/JAHA.121.021003. Epub 2021 Nov 02. PMID: 34726081; PMCID: PMC8751937.
Copy Download .nbib Format: NLM
Discovery of ciliary G protein-coupled receptors regulating pancreatic islet insulin and glucagon secretion.

Genes & development

Wu CT, Hilgendorf KI, Bevacqua RJ, Hang Y, Demeter J, Kim SK, Jackson PK.
PMID: 34385262
Genes Dev. 2021 Sep 01;35(17):1243-1255. doi: 10.1101/gad.348261.121. Epub 2021 Aug 12.

Multiple G protein-coupled receptors (GPCRs) are expressed in pancreatic islet cells, but the majority have unknown functions. We observed specific GPCRs localized to primary cilia, a prominent signaling organelle, in pancreatic α and β cells. Loss of cilia disrupts...

Cite
Wu CT, Hilgendorf KI, Bevacqua RJ, et al. Discovery of ciliary G protein-coupled receptors regulating pancreatic islet insulin and glucagon secretion. Genes Dev. 2021;35(17):1243-1255doi: 10.1101/gad.348261.121.
Wu, C. T., Hilgendorf, K. I., Bevacqua, R. J., Hang, Y., Demeter, J., Kim, S. K., & Jackson, P. K. (2021). Discovery of ciliary G protein-coupled receptors regulating pancreatic islet insulin and glucagon secretion. Genes & development, 35(17), 1243-1255. https://doi.org/10.1101/gad.348261.121
Wu, Chien-Ting, et al. "Discovery of ciliary G protein-coupled receptors regulating pancreatic islet insulin and glucagon secretion." Genes & development vol. 35,17 (2021): 1243-1255. doi: https://doi.org/10.1101/gad.348261.121
Wu CT, Hilgendorf KI, Bevacqua RJ, Hang Y, Demeter J, Kim SK, Jackson PK. Discovery of ciliary G protein-coupled receptors regulating pancreatic islet insulin and glucagon secretion. Genes Dev. 2021 Sep 01;35(17):1243-1255. doi: 10.1101/gad.348261.121. Epub 2021 Aug 12. PMID: 34385262; PMCID: PMC8415323.
Copy Download .nbib Format: NLM
SNAP25 mutation disrupts metabolic homeostasis, steroid hormone production and central neurobehavior.

Biochimica et biophysica acta. Molecular basis of disease

Hao X, Zhu B, Yang P, Dong D, Sahbaie P, Oliver PL, Shen WJ, Azhar S, Kraemer FB.
PMID: 34826585
Biochim Biophys Acta Mol Basis Dis. 2022 Feb 01;1868(2):166304. doi: 10.1016/j.bbadis.2021.166304. Epub 2021 Nov 24.

OBJECTIVE: SNAP-25 is one of the key proteins involved in formation of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes that are at the core of hormonal secretion and synaptic transmission. Altered expression or function of SNAP-25 can contribute...

Cite
Hao X, Zhu B, Yang P, et al. SNAP25 mutation disrupts metabolic homeostasis, steroid hormone production and central neurobehavior. Biochim Biophys Acta Mol Basis Dis. 2021;1868(2):166304doi: 10.1016/j.bbadis.2021.166304.
Hao, X., Zhu, B., Yang, P., Dong, D., Sahbaie, P., Oliver, P. L., Shen, W. J., Azhar, S., & Kraemer, F. B. (2022). SNAP25 mutation disrupts metabolic homeostasis, steroid hormone production and central neurobehavior. Biochimica et biophysica acta. Molecular basis of disease, 1868(2), 166304. https://doi.org/10.1016/j.bbadis.2021.166304
Hao, Xiao, et al. "SNAP25 mutation disrupts metabolic homeostasis, steroid hormone production and central neurobehavior." Biochimica et biophysica acta. Molecular basis of disease vol. 1868,2 (2022): 166304. doi: https://doi.org/10.1016/j.bbadis.2021.166304
Hao X, Zhu B, Yang P, Dong D, Sahbaie P, Oliver PL, Shen WJ, Azhar S, Kraemer FB. SNAP25 mutation disrupts metabolic homeostasis, steroid hormone production and central neurobehavior. Biochim Biophys Acta Mol Basis Dis. 2022 Feb 01;1868(2):166304. doi: 10.1016/j.bbadis.2021.166304. Epub 2021 Nov 24. PMID: 34826585; PMCID: PMC8759409.
Copy Download .nbib Format: NLM
ONBOARD: A Feasibility Study of a Telehealth-Based Continuous Glucose Monitoring Adoption Intervention for Adults with Type 1 Diabetes.

Diabetes technology & therapeutics

Tanenbaum ML, Ngo J, Hanes SJ, Basina M, Buckingham BA, Hessler D, Maahs DM, Mulvaney S, Hood KK.
PMID: 34270351
Diabetes Technol Ther. 2021 Dec;23(12):818-827. doi: 10.1089/dia.2021.0198.

No abstract available.

Cite
Tanenbaum ML, Ngo J, Hanes SJ, et al. ONBOARD: A Feasibility Study of a Telehealth-Based Continuous Glucose Monitoring Adoption Intervention for Adults with Type 1 Diabetes. Diabetes Technol Ther. 2021;23(12):818-827doi: 10.1089/dia.2021.0198.
Tanenbaum, M. L., Ngo, J., Hanes, S. J., Basina, M., Buckingham, B. A., Hessler, D., Maahs, D. M., Mulvaney, S., & Hood, K. K. (2021). ONBOARD: A Feasibility Study of a Telehealth-Based Continuous Glucose Monitoring Adoption Intervention for Adults with Type 1 Diabetes. Diabetes technology & therapeutics, 23(12), 818-827. https://doi.org/10.1089/dia.2021.0198
Tanenbaum, Molly L, et al. "ONBOARD: A Feasibility Study of a Telehealth-Based Continuous Glucose Monitoring Adoption Intervention for Adults with Type 1 Diabetes." Diabetes technology & therapeutics vol. 23,12 (2021): 818-827. doi: https://doi.org/10.1089/dia.2021.0198
Tanenbaum ML, Ngo J, Hanes SJ, Basina M, Buckingham BA, Hessler D, Maahs DM, Mulvaney S, Hood KK. ONBOARD: A Feasibility Study of a Telehealth-Based Continuous Glucose Monitoring Adoption Intervention for Adults with Type 1 Diabetes. Diabetes Technol Ther. 2021 Dec;23(12):818-827. doi: 10.1089/dia.2021.0198. PMID: 34270351.
Copy Download .nbib Format: NLM
Enhancing islet transplantation using a biocompatible collagen-PDMS bioscaffold enriched with dexamethasone-microplates.

Biofabrication

Primavera R, Razavi M, Kevadiya BD, Wang J, Vykunta A, Di Mascolo D, Decuzzi P, Thakor AS.
PMID: 33455953
Biofabrication. 2021 Jan 18; doi: 10.1088/1758-5090/abdcac. Epub 2021 Jan 18.

Islet transplantation is a promising approach to enable type 1 diabetic patients to attain glycemic control independent of insulin injections. However, up to 60% of islets are lost immediately following transplantation. To improve this outcome, islets can be transplanted...

Cite
Primavera R, Razavi M, Kevadiya BD, et al. Enhancing islet transplantation using a biocompatible collagen-PDMS bioscaffold enriched with dexamethasone-microplates. Biofabrication. 2021;doi: 10.1088/1758-5090/abdcac.
Primavera, R., Razavi, M., Kevadiya, B. D., Wang, J., Vykunta, A., Di Mascolo, D., Decuzzi, P., & Thakor, A. S. (2021). Enhancing islet transplantation using a biocompatible collagen-PDMS bioscaffold enriched with dexamethasone-microplates. Biofabrication, . https://doi.org/10.1088/1758-5090/abdcac
Primavera, Rosita, et al. "Enhancing islet transplantation using a biocompatible collagen-PDMS bioscaffold enriched with dexamethasone-microplates." Biofabrication vol. (2021). doi: https://doi.org/10.1088/1758-5090/abdcac
Primavera R, Razavi M, Kevadiya BD, Wang J, Vykunta A, Di Mascolo D, Decuzzi P, Thakor AS. Enhancing islet transplantation using a biocompatible collagen-PDMS bioscaffold enriched with dexamethasone-microplates. Biofabrication. 2021 Jan 18; doi: 10.1088/1758-5090/abdcac. Epub 2021 Jan 18. PMID: 33455953; PMCID: PMC8530023.
Copy Download .nbib Format: NLM
A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System.

Diabetes technology & therapeutics

Lum JW, Bailey RJ, Barnes-Lomen V, Naranjo D, Hood KK, Lal RA, Arbiter B, Brown AS, DeSalvo DJ, Pettus J, Calhoun P, Beck RW.
PMID: 33226840
Diabetes Technol Ther. 2021 May;23(5):367-375. doi: 10.1089/dia.2020.0535. Epub 2021 Apr 12.

No abstract available.

Cite
Lum JW, Bailey RJ, Barnes-Lomen V, et al. A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes Technol Ther. 2021;23(5):367-375doi: 10.1089/dia.2020.0535.
Lum, J. W., Bailey, R. J., Barnes-Lomen, V., Naranjo, D., Hood, K. K., Lal, R. A., Arbiter, B., Brown, A. S., DeSalvo, D. J., Pettus, J., Calhoun, P., & Beck, R. W. (2021). A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes technology & therapeutics, 23(5), 367-375. https://doi.org/10.1089/dia.2020.0535
Lum, John W, et al. "A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System." Diabetes technology & therapeutics vol. 23,5 (2021): 367-375. doi: https://doi.org/10.1089/dia.2020.0535
Lum JW, Bailey RJ, Barnes-Lomen V, Naranjo D, Hood KK, Lal RA, Arbiter B, Brown AS, DeSalvo DJ, Pettus J, Calhoun P, Beck RW. A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes Technol Ther. 2021 May;23(5):367-375. doi: 10.1089/dia.2020.0535. Epub 2021 Apr 12. PMID: 33226840; PMCID: PMC8080906.
Copy Download .nbib Format: NLM
Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers.

medRxiv : the preprint server for health sciences

Lee IT, Nakayama T, Wu CT, Goltsev Y, Jiang S, Gall PA, Liao CK, Shih LC, Schürch CM, McIlwain DR, Chu P, Borchard NA, Zarabanda D, Dholakia SS, Yang A, Kim D, Kanie T, Lin CD, Tsai MH, Phillips KM, Kim R, Overdevest JB, Tyler MA, Yan CH, Lin CF, Lin YT, Bau DT, Tsay GJ, Patel ZM, Tsou YA, Tai CJ, Yeh TH, Hwang PH, Nolan GP, Nayak JV, Jackson PK.
PMID: 32511516
medRxiv. 2020 May 12; doi: 10.1101/2020.05.08.20092866.

We investigated the expression and subcellular localization of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), within the upper (nasal) and lower (pulmonary) respiratory tracts of healthy human donors. We detected ACE2 protein expression within the cilia organelle of ciliated...

Cite
Lee IT, Nakayama T, Wu CT, et al. Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers. medRxiv. 2020;doi: 10.1101/2020.05.08.20092866.
Lee, I. T., Nakayama, T., Wu, C. T., Goltsev, Y., Jiang, S., Gall, P. A., Liao, C. K., Shih, L. C., Schürch, C. M., McIlwain, D. R., Chu, P., Borchard, N. A., Zarabanda, D., Dholakia, S. S., Yang, A., Kim, D., Kanie, T., Lin, C. D., Tsai, M. H., Phillips, K. M., Kim, R., Overdevest, J. B., Tyler, M. A., Yan, C. H., Lin, C. F., Lin, Y. T., Bau, D. T., Tsay, G. J., Patel, Z. M., Tsou, Y. A., Tai, C. J., Yeh, T. H., Hwang, P. H., Nolan, G. P., Nayak, J. V., & Jackson, P. K. (2020). Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.05.08.20092866
Lee, Ivan T, et al. "Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.05.08.20092866
Lee IT, Nakayama T, Wu CT, Goltsev Y, Jiang S, Gall PA, Liao CK, Shih LC, Schürch CM, McIlwain DR, Chu P, Borchard NA, Zarabanda D, Dholakia SS, Yang A, Kim D, Kanie T, Lin CD, Tsai MH, Phillips KM, Kim R, Overdevest JB, Tyler MA, Yan CH, Lin CF, Lin YT, Bau DT, Tsay GJ, Patel ZM, Tsou YA, Tai CJ, Yeh TH, Hwang PH, Nolan GP, Nayak JV, Jackson PK. Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers. medRxiv. 2020 May 12; doi: 10.1101/2020.05.08.20092866. PMID: 32511516; PMCID: PMC7273284.
Copy Download .nbib Format: NLM
Discontinued Use of the Loop Insulin Dosing System: A Mixed-Methods Investigation.

Diabetes technology & therapeutics

Wong J, Suttiratana S, Lal RA, Lum J, Lanning MS, Dunlap A, Arbiter B, Hanes S, Bailey R, Hood K, Naranjo D.
PMID: 34780283
Diabetes Technol Ther. 2021 Nov 15; doi: 10.1089/dia.2021.0362. Epub 2021 Nov 15.

BACKGROUND: Loop is an open-source automated insulin dosing system that allows users unrivaled control over system settings that effect future glucose prediction. Thousands use Loop, but little is known about those who discontinue.METHODS: In a large observational study, 874...

Cite
Wong J, Suttiratana S, Lal RA, et al. Discontinued Use of the Loop Insulin Dosing System: A Mixed-Methods Investigation. Diabetes Technol Ther. 2021;doi: 10.1089/dia.2021.0362.
Wong, J., Suttiratana, S., Lal, R. A., Lum, J., Lanning, M. S., Dunlap, A., Arbiter, B., Hanes, S., Bailey, R., Hood, K., & Naranjo, D. (2021). Discontinued Use of the Loop Insulin Dosing System: A Mixed-Methods Investigation. Diabetes technology & therapeutics, . https://doi.org/10.1089/dia.2021.0362
Wong, Jessie, et al. "Discontinued Use of the Loop Insulin Dosing System: A Mixed-Methods Investigation." Diabetes technology & therapeutics vol. (2021). doi: https://doi.org/10.1089/dia.2021.0362
Wong J, Suttiratana S, Lal RA, Lum J, Lanning MS, Dunlap A, Arbiter B, Hanes S, Bailey R, Hood K, Naranjo D. Discontinued Use of the Loop Insulin Dosing System: A Mixed-Methods Investigation. Diabetes Technol Ther. 2021 Nov 15; doi: 10.1089/dia.2021.0362. Epub 2021 Nov 15. PMID: 34780283.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 74 entries